Palmar plantar erythrodysesthesia epidemiology and demographics

Palmar plantar erythrodysesthesia Microchapters
Home
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Palmar plantar erythrodysesthesia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Palmar plantar erythrodysesthesia epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Palmar plantar erythrodysesthesia epidemiology and demographics
CDC on Palmar plantar erythrodysesthesia epidemiology and demographics
Palmar plantar erythrodysesthesia epidemiology and demographics in the news
Blogs on Palmar plantar erythrodysesthesia epidemiology and demographics
Directions to Hospitals Treating Palmar plantar erythrodysesthesia
Risk calculators and risk factors for Palmar plantar erythrodysesthesia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Epidemiology and demographics

PPE occurs in 6-42% of patients receiving chemotherapy.